Tacrolimus Treatment for Refractory Autoimmune Cytopenia

• Status: Unknown status
• Trial end date: 2021-11-10
• Target enrollment: 0
• Participant gender: All

Summary

Autoimmune cytopenia, including autoimmune hemolytic anemia (AIHA), pure red cell aplasia (PRCA), Evans syndrome (ES), usually has good responses to steroids therapies as first line, but there is a considerable percentage of patients who relapse, become refractory or dependent on steroids to maintain an acceptable level of hemoglobin or platelets. The effects of the second line therapy are also not satisfactory and sometimes not available. The investigators aim to explore the efficacy and side-effect of tacrolimus for refractory autoimmune cytopenia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking Union Medical College Hospital
• Treatments: Tacrolimus

Criteria

Inclusion Criteria:

• Refractory autoimmune cytopenia, including autoimmune hemolytic anemia, pure red cell aplasia, Evans syndrome.

• 18-80 years old.

• No response or intolerant to first and second line therapies.

• ECOG Performance Status of 0-2

• Written informed consent.

Exclusion Criteria:

• Other diseases which might cause hematological abnormalities.

• Response and well tolerate to first or second line therapy.

• Patients who are under 18-year-old or over 80-year-old.

• Pregnant or lactating.

• Patients unwilling to or unable to comply with the protocol.